Ibrutinib No Longer Approved for MCL, MZL: How This Change Will Affect Patients
The withdrawn approvals of ibrutinib for relapsed/refractory MCL and MZL are likely to have a limited impact on patients, experts say.
All articles by Mary Ellen Schneider
In the COVID-19 Era, Are In-Person Conferences Worth the Risks?
Conference organizers are taking steps to protect attendees from COVID-19, but some oncology professionals think more needs to be done.
- Loading...
Loading...
Loading... 
Loading...